is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference
TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatament of Diffuse Large B-cell Lymphoma
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group